Every year, nearly 300 million people in China, including over 50 million cough patients, get infected with respiratory diseases. It is estimated that the number of asthma patients in China has exceeded 20 million. Inhaled corticosteroids are suitable for the long-term treatment of bronchial asthma and can avoid all kinds of adverse reactions caused by systemic use of corticosteroids. At present, the main inhaled corticosteroids used in clinical practice are Budesonide, Fluticasone and Beclomethasone.
Full report: Investigation Report on China Budesonide Market, 2018-2022
In the 1990s, Budesonide was successfully developed by AstraZeneca to be used for the treatment of non-corticosteroid dependent or corticosteroid-dependent bronchial asthma and chronic obstructive pulmonary disease. In Jun. 1997, Budesonide aerosol was approved by the FDA.
In 1994, China approved the import of Budesonide. In 1995, Astra (Wuxi) Pharmaceutical was approved to manufacture and sell Budesonide in China. Budesonide has been developing rapidly since it entered the Chinese market. Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%. There is a high demand for Budesonide in China. The majority of Budesonide currently sold on the market are manufactured by AstraZeneca, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical Co., Ltd., Orion Pharma and Shanghai Sine Pharmaceutical Laboratories Co., Ltd. In terms of sales, AstraZeneca has the highest market share, accounting for more than 90% of the Chinese market in 2017.
Owing to the aggravating environmental pollution and ageing population, China will see a rising incidence of respiratory diseases from 2018 to 2012, which will lead to an ever-expanding Budesonide market.